RougeTx has launched with a $58 million series A financing to advance RTX‑001, a potential once‑daily oral treatment designed to restore blood vessel stability in HHT. The round was co‑led by BGV, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures.
The funding will support RTX‑001 as it progresses toward first‑in‑human development. HHT is the second most common inherited bleeding disorder, caused by abnormal blood vessel formation known as AVMs. These can lead to recurrent nose and gastrointestinal bleeding, iron deficiency, chronic anemia and serious complications affecting major organs. There are currently no approved therapies for HHT.
Andrew Lightfoot, Chief Executive Officer at RougeTx, said: “RTX-001 is designed to stabilize fragile blood vessels by restoring pericyte attachment. The data we have generated for RTX-001 gives us a strong foundation as we move toward the clinic. This financing also allows us to explore where the same biology may impact other vascular diseases.”
Franck Lebrin, Co‑Founder and Scientific Advisor at RougeTx, remarked: “RougeTx represents the culmination of more than 20 years of research, initially at Inserm and over the past decade in my laboratory at Leiden University Medical Center. I am excited by the opportunity to bring a novel treatment to the HHT community.”
Sandra Glucksmann, Executive Chair at RougeTx, noted: “For too long, people living with HHT have faced a serious, lifelong disease with no approved treatment options. RougeTx was founded with a commitment to this community and a belief that advances in vascular biology can finally make a meaningful difference for patients and families. We are grateful to our investors for their support and shared commitment to our mission.”
RougeTx’s periSCOPE platform is designed to expand the pipeline beyond HHT, identifying new treatment opportunities in diseases driven by vascular instability and supporting development of small‑molecule therapies based on shared underlying biology.
